TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30037726
Drug: ACR of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR of 30 to 299 mg/g
Study: 30037726
Drug: ACR ≥
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACR ≥ 300 mg/g
Study: 19352063
Drug: BCAA drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA drink (0.4% BCAA, 4% carbohydrate; 1,500 mL/d)
Study: 8873503
Drug: Alendronate 40
Normalized name: ALENDRONATE 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 40 mg/day
Study: 9110064
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (500 mg six times daily)
Study: 9110064
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg once daily)
Study: 1748537
Drug: Liquid prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid prepared from effervescent IP tablets
Study: 27578231
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 4mg in 10mL of saline
Study: 23378709
Drug: Low-fluence Q-switched
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence Q-switched Nd: YAG laser (QSNYL) at weekly intervals
Study: 23378709
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% azelaic acid cream applied twice daily
Study: 23378709
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-fluence QSNYL and topical 20% azelaic acid cream
Study: 20529547
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose potassium sodium hydrogen citrate (1 g/d)
Study: 20529547
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose potassium sodium hydrogen citrate (2 g/d)
Study: 20529547
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of PSHC (1 g/d and 2 g/d)
Study: 12486491
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg infusion
Study: 28254171
Drug: Weekly food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly food provision reflecting this advice (n = 148)
Study: 21075681
Drug: Cyproheptadine hydrochloride
Normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine hydrochloride (serotonin receptor 5-HT2 antagonist)
Study: 19548855
Drug: Sustained-release fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release fampridine (fampridine SR)
Study: 17095643
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g bovine colostrum protein concentrate (CPC)/day
Study: 14507547
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for bulimia nervosa
Study: 11054194
Drug: Glucagon 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon 0.03 mg/kg
Study: 1443818
Drug: 2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg‐1 of ketamine
Study: 1443818
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of normal saline)
Study: 31657615
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement containing two genera and five species of bacteria
Study: 28278361
Drug: Individualised nurse-led
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualised nurse-led home exercise prescription and behavioural support for 12 weeks
Study: 28278361
Drug: In-centre group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-centre group exercise training weekly for 6 weeks
Study: 25473823
Drug: Intermittent lower-body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent lower-body negative pressure (LBNP) therapy for 60 min daily after exercise
Study: 25473823
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LBNP therapy)
Study: 24350408
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 1 g every eight hours (q8h) for 24 hours
Study: 24350408
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of 1 g q8h for 24 hours
Study: 24350408
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of 2 g q8h for 24 hours
Study: 24350408
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion regimens
Study: 19604597
Drug: Extended information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended information regarding new influenza drugs
Study: 19604597
Drug: Limited information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited information regarding new influenza drugs
Study: 17245718
Drug: IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2a treatment
Study: 14982567
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg ml(‐1)
Study: 11273575
Drug: Natural work-life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural work-life intervention allowing up to five days of self-administered sick leave with full financial compensation up to four times a year.
Study: 26268104
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement with micronutrients and plant extracts
Study: 21572981
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral ivermectin (200 microgram/kilogram body weight)
Study: 21572981
Drug: Double doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double doses of oral ivermectin (given 2 weeks apart)
Study: 21572981
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of oral albendazole (800 mg daily)
Study: 19880462
Drug: Second-generation antidepressants
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antidepressants (various types)
Study: 19880462
Drug: Policies that
Normalized name: Polistes fuscatus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policies that improve access to care (e.g., encouraging primary care treatment of depression)
Study: 19880462
Drug: Policies that
Normalized name: Polistes fuscatus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policies that promote treatment adherence (e.g., pay-for-performance initiatives)
Study: 16214831
Drug: Ablation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation and antiarrhythmic drug therapy
Study: 16214831
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy alone (control group)
Study: 12525441
Drug: Flutamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (125 mg/day) + Metformin (1275 mg/day) + Low-dose Oral Contraceptive (ethinyl estradiol 20 microg + gestodene 75 microg)
Study: 12525441
Drug: Flutamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (125 mg/day) + Metformin (1275 mg/day)
Study: 6123806
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and steroids (control)
Study: 24774721
Drug: Hypofractionated carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypofractionated carbon ion radiation therapy (64 GyE in 16 fractions)
Study: 24774721
Drug: Hypofractionated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated proton radiation therapy (64 GyE in 16 fractions)
Study: 24774721
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (carbon ion and proton therapy)
Study: 18928998
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (1000 mg or less intravenously over 15 minutes, repeated weekly to a maximum of 2500 mg)
Study: 29858106
Drug: H.E.L.P.-apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.L.P.-apheresis
Study: 10687932
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (prednisolone, dextranes, pentoxifyllin)
Study: 1925896
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor positive (ER+) tumors (greater than or equal to 3 femtomoles per milligram cytosol of protein)
Study: 1925896
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor negative (ER-) tumors (less than 3 femtomoles per milligram cytosol protein)
Study: 6918220
Drug: Mevinolin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 5 mg
Study: 6918220
Drug: Mevinolin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 15 mg
Study: 6918220
Drug: Mevinolin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 50 mg
Study: 30793994
Drug: Caffeine intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine intervention: 216 mg caffeine from coffee beverages made from 6 g pure coffee beans (36 mg of caffeine per gram).
Study: 30793994
Drug: Control: 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: 200 mg lactose without caffeine.
Study: 23043923
Drug: Yiqiyangxin Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqiyangxin Chinese medicine compound combined with cognitive therapy
Study: 23043923
Drug: Paroxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine combined with cognitive therapy
Study: 18444446
Drug: Sufentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil + Haloperidol 3 mg/h infusion
Study: 18444446
Drug: Sufentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil + Propofol 25 microg/kg/min infusion
Study: 18444446
Drug: Sufentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil + Midazolam 0.04 mg/kg/h infusion
Study: 18444446
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion (Control group)
Study: 1681918
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g intravenously at the time of skin incision (Group I, n = 112)
Study: 1681918
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g intravenously at the time of skin incision, followed by a second dose eight hours later (Group II, n = 107)
Study: 6627831
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Acetaminophen (concurrent use)
Study: 27774917
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary calcium meal (HDCM; 547 mg DC)
Study: 27774917
Drug: High supplemental
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High supplemental calcium meal (HSCM; 500 mg SC-calcium carbonate)
Study: 27774917
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium meal (LCM; 42 mg DC)
Study: 15613414
Drug: Testosterone patches
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patches (300 mcg testosterone over 24 hours, applied twice weekly)
Study: 9527734
Drug: Propofol 30
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 30 mg x h(‐1)
Study: 9527734
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion (Intralipid) 3 ml x h(‐1)
Study: 1148032
Drug: Halofenate (MK-185,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofenate (MK-185, 1 g/day)
Study: 24122944
Drug: MK-7288 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7288 (10, 20 mg)
Study: 18727657
Drug: SRP+MTZ+AMX (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+MTZ+AMX (metronidazole 400 mg 3 x per day and amoxicillin 500 mg 3 x per day for 14 days)
Study: 18727657
Drug: SRP+MTZ (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+MTZ (metronidazole 400 mg 3 x per day for 14 days)
Study: 14583903
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (monthly consultations for 6 months)
Study: 8765459
Drug: Topical Aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Aloe vera extract 0.5% in a hydrophilic cream
Study: 7933528
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem) at a dose of 10 mg/kg and 12 mg/kg
Study: 28175295
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg followed by 2 mg/kg if necessary)
Study: 28175295
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg followed by another 1 mg if necessary)
Study: 27253482
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of vitamin D3 and 1500 mg of calcium daily; 50,000 IU of ergocalciferol (vitamin D2) weekly for vitamin D deficient and insufficient patients until levels normalized or fractures healed.
Study: 19196106
Drug: Splinting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splinting plus low-level laser (LLL) therapy
Study: 16946685
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy (0.625 mg of conjugated equine estrogens per tablet)
Study: 16946685
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen therapy (0.625 mg conjugated equine estrogens per 1 g vaginal cream)
Study: 8842586
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 1 mg gemeprost every 6 hours (Group I)
Study: 8842586
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 0.5 mg gemeprost every 6 hours (Group II)
Study: 8842586
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 5 x 1 mg gemeprost every 3 hours if abortion had not occurred after 24 hours
Study: 8842586
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (0.5 mg)
Study: 1519677
Drug: Tramadol (642
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (642 mg)
Study: 1519677
Drug: Tramadol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (0.5, 1.0, and 2.0 mg.kg‐1)
Study: 1519677
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (0.143 mg.kg‐1)
Study: 29038236
Drug: Prochlorperazine 5
Normalized name: prochlorperazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 5 mg, given three times daily for 5 days
Study: 29038236
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given three times daily for 5 days
Study: 26012345
Drug: Dexmedetomidine 0.38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.38 μg/kg
Study: 19365139
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D dose decreased
Study: 19365139
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D dose increased
Study: 17515459
Drug: Reminder for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminder for use of beta-blockers
Study: 15601388
Drug: Landiolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.1 mg/kg)
Study: 9369918
Drug: Consolidating WBI
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidating WBI after systemic chemotherapy
Study: 1245147
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g L-dopa
Study: 1245147
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g L-dopa and 1.0 g L-tryptophan
Study: 28222947
Drug: Stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization splint therapy following arthrocentesis
Study: 28222947
Drug: Splint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint therapy only
Study: 23507090
Drug: Self-reported prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported prescription filling
Study: 11274308
Drug: Rapid initiation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid initiation (900 mg/day immediately following the placebo lead-in)
Study: 11274308
Drug: Slow initiation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow initiation (300 mg day 1, 600 mg day 2, then 900 mg/day)
Study: 9249101
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + D (Dopamine infusion during epidural anesthesia)
Study: 7685682
Drug: diclofenac/misoprostol 50mg/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac/misoprostol 50mg/200 micrograms 2 or 3 times daily
Study: 3323368
Drug: ICRC antileprosy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRC antileprosy vaccine (0.5 x 10(9) or 1.7 x 10(7) bacilli, intradermally)
Study: 19900209
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with OloGen implant
Study: 19900209
Drug: Trabeculectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trabeculectomy without OloGen implant (control group)
Study: 18559917
Drug: AG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AG infusion
Study: 18559917
Drug: Naloxone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.1 mg/kg iv as a slow bolus)
Study: 10608295
Drug: Colostrinin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrinin (100 microg per tablet, every second day)
Study: 10608295
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available bioorganic selenium (100 microg selenium per tablet, every second day)
Study: 7477801
Drug: Combined cognitive‐behavioral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive‐behavioral, nutritional and antidepressant therapy (7 with amineptine and 6 with fluoxetine)
Study: 1951111
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (15, 30, 45, 60, 75, 90, and 105 mg/24 hours)
Study: 1951111
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (various doses)
Study: 1951111
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (highest dose)
Study: 7028786
Drug: PGI2 infusion
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 infusion at 0.1 ng/kg per min
Study: 7028786
Drug: PGI2 infusion
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 infusion at 0.4 ng/kg per min
Study: 7028786
Drug: PGI2 infusion
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 infusion at 2.0 ng/kg per min
Study: 7028786
Drug: Control (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vehicle infusion)
Study: 7028786
Drug: Exogenous PGI2
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous PGI2 infusion rates
Study: 12959951
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg slow-release caffeine (SRC) from recovery day 1 (D1) to D5 (0800)
Study: 12959951
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin (Mlt) on preflight D-1 (1700), flight day D0 (1600), and from D1 to D3 (2300)
Study: 12166613
Drug: Nimesulide (2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (2.9 mg/kg)
Study: 12166613
Drug: Diclofenac (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (3.0 mg/kg)
Study: 12166613
Drug: Celecoxib (12.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (12.7 mg/kg)
Study: 12166613
Drug: Rofecoxib (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (3.0 mg/kg)
Study: 12166613
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Nimesulide, Diclofenac, Celecoxib, Rofecoxib)
Study: 7865386
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclophosphamide and low-dose corticosteroids
Study: 2744314
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg q.i.d.)
Study: 194524
Drug: Antibiotic-corticosteroid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-corticosteroid solution